MedTrace Logo

A Study of AST-008 in Healthy Subjects

NCT03086278 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2018-09-25

No results posted yet for this study

Summary

AST-008 will be dosed subcutaneously to healthy volunteers in a combined SAD/MAD study to evaluate its safety, tolerability, pharmacokinetics and pharmacodynamics.

Conditions

  • Healthy Volunteer Study

Interventions

DRUG

AST-008

AST-008 is a toll-like receptor 9 agonist.

Sponsors & Collaborators

  • Exicure, Inc.

    lead INDUSTRY

Study Design

Purpose
SCREENING
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-20
Primary Completion
2018-08-16
Completion
2018-08-16
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03086278 on ClinicalTrials.gov